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ABSTRACT 
Verplaetse, Terril L. M.S., Purdue University, December 2011. Effects of Prazosin 
Treatment on Ethanol- and Sucrose-Seeking and Intake in P Rats. Major Professor: 
Cristine Czachowski. 
 
 
 
Background:  Previous studies show that prazosin, an α1-adrenergic receptor antagonist, 
decreases alcohol drinking in animal models of alcohol use and dependence and in 
alcohol-dependent men.  These studies extended previous findings by using a paradigm 
that allows for separate assessment of prazosin on motivation to seek versus consume 
ethanol or sucrose in selectively bred rats given acute or chronic prazosin treatment.  
Methods:  Alcohol-preferring P rats were trained to complete an operant response that 
resulted in access to either 2% (Exp. 1) or 1% (Exp.2) sucrose or 10% ethanol.  In 
Experiment 1, a 4-week consummatory testing phase consisted of rats bar-pressing to 
“pay” a specified amount up front to gain access to unlimited ethanol (or sucrose) for a 
20-minute period. A 4-week appetitive testing phase examined how much the rats would 
bar-press for ethanol in an extinction session when no reinforcer could be obtained. In 
Experiment 2, during testing, the response requirement was dropped to a 1 and daily 
session cycles of drug (3 weeks/ 14 sessions from Tues to Fri) or vehicle (2 weeks/ 9 
sessions from Tues to Fri) treatment were alternated per drug dose for a total of 3 drug 
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doses (3 cycles) per rat.  After each drug cycle, a single non-reinforced extinction session 
was conducted with no drug ‘on board’ and no reinforcer access.  On test days, rats were 
given IP injections of either vehicle or one of three doses of prazosin (Exp 1: 0.5, 1.0, 1.5 
mg/kg; Exp 2: 0.25, 0.5, 1.0 mg/kg; balanced design; -30 min). Results:  In Experiment 1, 
prazosin significantly decreased ethanol-seeking at all doses tested.  The highest dose 
decreased ethanol intake and increased the latency to first lever-press and first lick.  
Sucrose-seeking and intake were decreased by the same doses of prazosin.  In 
Experiment 2, prazosin significantly decreased reinforcer-seeking at the lowest and 
highest doses while ethanol intake was not decreased by prazosin.  Conversely, sucrose-
seeking was decreased at the highest dose of prazosin tested while sucrose consumption 
was decreased by all doses.  Latency to lever-press for sucrose was increased by the 
lowest dose of prazosin compared to vehicle.  Conclusions:  These findings extend 
previous research and indicate that prazosin decreases motivation to seek ethanol and 
sucrose.  The specificity of prazosin on different behaviors and over different reinforcers 
suggests that these findings are not due to prazosin-induced motor-impairment or 
malaise.  These data suggest that prazosin may work by decreasing the reinforcing 
properties of reinforcers in general. 
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 INTRODUCTION 
Alcohol is the most commonly used brain depressant affecting as many as 90% of 
adults in the United States with approximately 30-60% of those individuals having an 
adverse alcohol-related event at some point in their lives (American Psychiatric 
Association [APA], 1994).  Furthermore, lifetime alcohol dependence amongst alcohol 
users is 20.1%  (Grant et al., 1997) and the average volume of alcohol consumed has 
been found to increase the risk for alcohol use disorders, hypertension, cancer and a 
variety of other medical conditions (Rehm et al., 2003).  Currently, there are only three 
major drugs on the market used to treat alcohol abuse (naltrexone, acamprosate, and 
disulfiram) and all three have limitations regarding their efficacy and use (Garbutt et al., 
1999; Kranzler and Van Kirk, 2001).  Clinical studies reveal that naltrexone attenuates 
the risk to relapse to heavy drinking and decreases the frequency of drinking days but 
does not affect abstinence (Garbutt et al., 1999; Kranzler and Van Kirk, 2001).  
Acamprosate also reduces the frequency of drinking in that cumulative abstinent days are 
decreased (Kranzler and Van Kirk, 2001).  Finally, the use of disulfiram yields mixed 
outcomes when given as a treatment for alcohol dependence in that it occasionally 
decreases the frequency of drinking but has no effect on improving abstinence (Garbutt et 
al., 1999).  These treatments are efficacious in reducing the frequency of alcohol 
consumption but their specific role in treating alcohol use disorders is unclear.  New 
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pharmacotherapeutic treatments need to be studied in order to more clearly define how to 
treat and manage alcohol abuse. 
 
Alcohol and Anxiety 
Alcohol use disorders and anxiety disorders have consistently been found to be 
comorbid in clinical populations with different types of anxiety disorders relating more 
closely to alcohol use problems (Brady et al., 2000; Kushner et al., 1990).  The literature 
remains mixed as to whether individuals start drinking to relieve anxiety (i.e. anxiety 
disorders precede the onset of alcohol use disorders) or whether the withdrawal 
symptoms associated with alcohol use disorders contributes to the development of an 
anxiety/ stress disorder.  Alcohol-related problems tend to begin from attempts to self-
medicate in individuals with social phobia but panic disorder and generalized anxiety 
disorder have been found to stem from alcohol abuse (Kushner et al., 1990).  Consistent 
with these findings, there is a high comorbidity rate of alcohol abuse and post-traumatic 
stress disorder (PTSD) (Brady et al., 2000).  Patients with comorbid PTSD and alcohol 
use disorders displayed more avoidance and arousal symptoms as well as an increase in 
sleep disturbances compared to patients with PTSD only (Saladin et al., 1995).  Increased 
arousal symptoms in patients with alcohol use disorders and PTSD may be due to an 
increase in noradrenergic functioning.  Specifically, patients with PTSD have been shown 
to have excessive noradrenergic firing (Southwick et al., 1993; 1999), and in rodent 
models, depletion of norepinephrine is associated with a decrease in ethanol self-
administration (Davis et al., 1978).  Taken together, the excessive noradrenergic 
signaling seen in stress disorders such as PTSD and the fact that norepinephrine depletion 
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reduces ethanol self-administration suggests that excessive noradrenergic functioning 
plays a key role in maintaining these two disorders. 
 
Prazosin Background 
Prazosin, an α1-adrenergic receptor antagonist, works by reducing central 
adrenergic activity by means of blocking norepinephrine binding to postsynaptic 
receptors (Simpson et al., 2009) in several brain areas including but not limited to the 
locus coeruleus (Unnerstall, 1987), olfactory bulb, cerebral cortex, amygdala, dentate 
gyrus, and the thalamus (Pieribone et al., 1994).  Prazosin, although primarily used as an 
α1 antagonist and with significantly higher affinity for the α1 receptor, also binds with 
modest affinity to α2-adrenoceptors (Boyajian and Leslie, 1987).  Prazosin is unique 
amongst α1 antagonists in that it is active at central nervous system sites when 
administered peripherally (Menkes et al., 1981).  The drug was originally marketed as 
“Minipress” by Pfizer Pharmaceuticals and is currently used as an antihypertensive drug 
(Constantine et al, 1973).  Since prazosin works as a centrally active α1-adrenergic 
antagonist, Raskind and colleagues (2003) hypothesized that prazosin should counteract 
excessive noradrenergic activity reported in PTSD patients and, therefore, should reduce 
symptoms seen in PTSD.  Clinical studies provide evidence that prazosin decreases 
stressful symptoms related to PTSD, specifically distressing nightmares and night 
awakenings (Raskind et al., 2003; 2007).  Interestingly, patients receiving prazosin 
treatment for PTSD also reported a decrease in motivation to drink alcohol and a decrease 
in alcohol intake (Raskind, unpublished observations).  These findings, coupled with 
findings that chronic ethanol exposure and withdrawal in Spraque-Dawley rats caused 
4 
 
 
defects in HPA function, increases in sympthoadrenal activation during abstinence, and 
increases in anxiety suggesting alterations in the noradrenergic system related to alcohol 
use (Rasmussen et al., 2001; 2006), and the high comorbidity rate of alcohol use 
disorders and PTSD (Brady et al., 2000), led to the examination of prazosin as a 
treatment for alcohol abuse.  Subsequently, prazosin has been found to decrease drug 
self-administration in animal models of drug abuse and to reduce alcohol drinking and 
craving in alcohol-dependent men (Bruijnzeel et al., 2010; Forget et al., 2010; Greenwell 
et al., 2009; Le et al., 2011; Rasmussen et al., 2009; Simpson et al., 2009; Walker et al., 
2008).   
    Prazosin has been shown to decrease the reinforcing properties of nicotine and 
heroin self-administration (Bruijnzeel et al., 2010; Forget et al., 2010; Greenwell et al., 
2009).  Prazosin dose-dependently reduced heroin self-administration during the first 
hours of access in Wistar rats trained with extended 12 hr/day access to intravenous 
heroin self-administration (Greenwell et al., 2009).  Likewise, prazosin dose-dependently 
decreased the self-administration of nicotine in Long Evans rats with the strongest 
decrease at the 1 mg/kg dose (Forget et al., 2010).  This decrease in self-administration 
was maintained over consecutive daily sessions of nicotine self-administration (Forget et 
al., 2010).  Forget and colleagues (2010) also found that prazosin dose-dependently 
decreased reinstatement of extinguished nicotine seeking induced by a nicotine prime or 
nicotine cues.  Furthermore, Bruijnzeel et al. (2010) found that prazosin dose-
dependently decreased the elevations in brain reward thresholds associated with nicotine 
withdrawal in Wistar rats. 
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Four studies to date have tested the hypothesis that prazosin would be effective in 
reducing the reinforcing properties of alcohol (Le et al., 2011; Rasmussen et al., 2009; 
Simpson et al., 2009; Walker et al., 2008).  Prazosin has been found to block dependence-
induced increases in operant responding for ethanol in Wistar rats at doses of 1.5 and 2.0 
mg/kg (Walker et al., 2008).  Interestingly, non-dependent animals increased responding 
for ethanol at the 0.25 mg/kg dose and decreased responding at the 2.0 mg/kg dose of 
prazosin (Walker et al., 2008).  Similarly, prazosin has been found to decrease ethanol 
drinking in alcohol-preferring (P) rats in a 2-hour, 2-bottle choice (ethanol versus water) 
paradigm which tested the effects of prazosin in a 2-day treatment and in a subsequent 
“chronic” 5-day treatment (Rasmussen et al., 2009).  It is interesting to note that the 
lowest dose of prazosin (0.5 mg/kg) did not reduce alcohol consumption in the 2-day 
treatment but exhibited an effect after three days of administration in the subsequent 5-
day treatment (Rasmussen et al., 2009).  Likewise, the highest doses of prazosin lost 
effectiveness after three days of treatment (Rasmussen et al., 2009).  Further, prazosin 
has been found to block yohimbine-induced reinstatement of ethanol seeking in Wistar 
rats as well as footshock-induced reinstatement of ethanol seeking in Long Evans rats (Le 
et al., 2011).  Yohimbine is an α2-adrenoceptor antagonist that increase norepinephrine 
release in the brain.  Finally, prazosin has been shown to decrease relapse alcohol 
drinking in treatment-seeking, alcohol-dependent men without PTSD (Simpson et al., 
2009).  Subjects receiving prazosin treatment reported fewer drinking days per week and 
fewer drinks per week than the placebo group during the last three weeks of the 6-week 
study (Simpson et al., 2009).   
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 Prazosin, the α1-adrenergic receptor antagonist, has therefore been shown to 
decrease the reinforcing properties of ethanol in animal models using three different 
paradigms and in a pilot clinical study (Le et al., 2011; Rasmussen et al., 2009; Simpson 
et al., 2009; Walker et al., 2008).  Prazosin has also been effective in reducing the 
reinforcing properties of nicotine and heroin (Bruijnzeel et al., 2010; Forget et al., 2010; 
Greenwell et al., 2009).  Since prazosin administration has been successful in decreasing 
the reinforcing value of alcohol and other drugs, I first investigated the effects of acute 
prazosin administration on the motivation to initiate ethanol-seeking and drinking (see 
Experiment 1).  
 
Alcohol-Preferring (P) Rat 
Animal models of alcohol abuse and alcoholism are necessary in order to study 
new pharmacotherapeutic treatments for alcohol use disorders.  The alcohol-preferring 
(P) rat is one such model that was developed to study excessive ethanol drinking.  P rats 
are less sensitive to the sedative effects of ethanol and are more susceptible to the 
stimulatory effects of ethanol as opposed to their non-preferring (NP) counterparts (Bell 
et al., 2002; Gatto et al., 1987; Stewart et al., 1991).  Ethanol self-administration has been 
found to increase locomotor activity and heart rate in P rats (Bell et al., 2002) while P rats 
have also been found to develop tolerance to the motor impairing (Gatto et al., 1987) and 
aversive effects (Stewart et al., 1991) of ethanol.  In fact, P rats will drink greater than 5 
g/kg/day ethanol, achieving pharmacologically relevant blood ethanol concentrations, 
compared to 1 g/kg/day in their non-preferring counterpart (Li et al., 1987).  
Additionally, P rats will work for ethanol access in that they will operantly respond for 
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ethanol in concentrations up to 30% and show preference for ethanol over water whereas 
NP rats won’t respond for ethanol above concentrations of 10% (Murphy et al., 1989).  P 
rats have also been found to increase responding for ethanol after repeated deprivation 
periods (Rodd et al., 2003).  Moreover, P rats have been found to self-administer ethanol 
for its pharmacological effects as opposed to its taste or caloric value (Gatto et al., 1994; 
Murphy et al., 1988).  P rats will respond to self-administer ethanol intragastrically 
(Murphy et al., 1988) and will self-administer ethanol directly into the ventral tegmental 
area (Gatto et al., 1994).  Finally, evidence suggests that P rats exhibit withdrawal 
symptoms after chronic ethanol consumption (Waller et al., 1982) and relapse-like 
behavior is exhibited in P rats in the form of the alcohol deprivation effect after chronic 
consumption (Rodd-Henricks et al., 2000).  Interestingly, evidence also suggests that 
animal models genetically bred for high ethanol consumption may exhibit a down-
regulation of norepinephrine transporters in the locus ceruleus (Murphy et al., 2002), a 
brain region involved in the stress response and a major site of CNS norepinephrine 
synthesis.   
Important to the present experiments is the consideration that selecting rats for 
high alcohol preference might also inadvertently select for other traits.  Again, clinical 
studies have consistently shown that alcohol use disorders and anxiety disorders are 
highly comorbid (Brady et al., 2000; Kushner et al., 1990) and findings suggest a 
relationship between noradrenergic activity, stress, and ethanol use (Davis et al., 1978; 
Raskind et al., 2003; Southwick et al., 1993;1999).  Animal models of high alcohol 
preference have shown that P rats display an increase in footshock –induced suppression 
of operant responding as well as a decreased latency in the open arms of the elevated plus 
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maze and longer time in the passive avoidance test compared to their NP counterpart 
(Stewart et al., 1993), indicating that selective breeding for high alcohol drinking in 
rodent lines might also select for high stress and anxiety 
 
The ‘Sipper-Tube’ Paradigm 
Prazosin has been shown to decrease ethanol self-administration in rats in two 
different behavioral paradigms.  The behavioral paradigms previously utilized focus on 
an exclusive consummatory response (i.e., home-cage drinking) (Rasmussen et al., 2009) 
or a combined seeking/drinking response (i.e. lever-press required for access to each 
0.1ml of the reinforcer solution) (Walker et al., 2008).  The acute prazosin administration  
study (Experiment 1) and the chronic prazosin treatment study (Experiment 2) further 
examined the effects of seeking and drinking in a paradigm that separately assesses the 
ethanol (or sucrose) seeking response (i.e. lever-presses) from the consummatory 
response (i.e. drinking) (Samson and Czachowski, 2002).  Other models of ethanol- 
seeking and consumption often measure these behaviors while the animal is under the 
influence of the pharmacological effects of ethanol thus seeking of the drug cannot be 
accurately assessed (Samson and Czachowski, 2002).  The ‘sipper-tube’ model utilizes a 
response requirement that the animal has to emit before gaining access to twenty minutes 
of free access to ethanol (consummatory behaviors) so operant behavior is not affected by 
the pharmacological properties of the ethanol.  This paradigm also measures seeking (or 
craving) with no ethanol ‘on board’ thus accurately measuring if the animal will seek the 
reinforcing properties of ethanol when no reinforcer can be obtained.  Thus, the ‘sipper-
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tube’ paradigm examines seeking and intake within an operant session and in completely 
separate phases.  This model has effectively demonstrated that a drug can exclusively 
affect reinforcer-seeking verses drinking (Czachowski et al., 2001a; Czachowski et al., 
2001b; Czachowski et al., 2002) and that rats will self-administer ethanol to binge-like 
levels in 20-minute free access sessions (Samson and Czachowski, 2002).   
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EXPERIMENT 1 
Introduction 
The goal of Experiment 1 was to further examine the acute effects of prazosin 
administration on ethanol (or sucrose)-seeking and intake.  As noted in the general 
introduction, P rats were used in the ‘sipper-tube’ paradigm which procedurally separates 
consummatory (intake) and appetitive (seeking) behaviors.  This model allows for the 
measurement of start latencies, lever-presses (seeking), reinforcer intake (drinking), and 
number of licks.  Prazosin dosing was similar to previous studies in which doses ranged 
from 0.25 mg/kg to 2.0 mg/kg and were injected intraperitoneally (IP) 30 minutes prior to 
the start of the operant session.  Based on previous findings, it was hypothesized that 
prazosin, tested in the P rat, would dose-dependently decrease ethanol responding and 
intake while no effect of prazosin would be seen in the sucrose-reinforced group. 
 
Materials and Methods 
Subjects 
Sixteen alcohol-naïve, P rats from the sixty-eighth generation of selective 
breeding served as subjects in one of two groups (ethanol group, n=8 and sucrose group, 
n=8).   Rats were individually housed with food and water available ad libitum except as 
noted below.  The animals were maintained on a 12-hour light/dark cycle (lights on 
from7 AM to 7 PM), and animal care was in accordance with NIH guidelines (Guide for 
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the Care and Use of Laboratory Animals; NIH Guide 1996) and approved by the 
Institutional Animal Care and Use Committee. 
 
Apparatus 
Daily sessions were conducted in operant chambers (Med-Associates; St. Albans, 
VT, USA; 30 x 30 x 24.5 cm) equipped with a house light, one retractable lever, and a 
retractable graduated cylinder tube with a rubber stopper and stainless steel spout with 
double ball bearings to prevent leakage.  The lever was located on the opposite wall to 
the sipper tube drinking bottle.  Solution became available upon completing the response 
requirement on the lever.  Operant chambers were individually housed in ventilated, 
sound-attenuating enclosures to minimize disturbances.  Electrical inputs and outputs 
were controlled using Med-Associates software (Med-Associates). 
 
Drugs 
Ethanol solutions were prepared volume/volume in water using 95% ethanol.  
Sucrose/ethanol solutions and sucrose solutions were prepared weight/volume and used 
as a solute.  Prazosin hydrochloride (Sigma-Aldrich, Inc., St. Louis, MO) was dissolved 
in sterile water at 2 ml/kg BW.  Prazosin was injected IP in a dose of 0.0, 0.5, 1.0, or 1.5 
mg/kg BW, 30 minutes prior to operant sessions.  Prazosin was given 30 minutes prior to 
the start of the operant session based on an onset of action between 5-40 minutes 
(Menkes et al., 1981).  
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Training and Ethanol Initiation 
 Upon arrival, subjects were weighed and handled for a minimum of three days.  
Daily sessions were conducted five days/week at the same time each day during the 
lights-on cycle.  Subjects were initially trained to press the lever on a fixed-ratio (FR) one 
schedule that resulted in 15 seconds of access to the sipper tube with 10% sucrose in 
approximately 30 minute sessions.  Subjects were water restricted for the initial sessions 
only, after which food and water were available ad libitum in the home cage.  Operant 
training was carried out over a 3 week period using the sucrose-fading procedure 
(Samson, 1986).  The sucrose fading procedure involves increasing the FR from 1 to 4 
while decreasing the sucrose concentration to 2%, and in the ethanol group introducing 
ethanol and increasing the concentration from 2% to 10% while fading out sucrose 
completely with final solutions reaching 2% sucrose for the sucrose group and 10% 
ethanol for the ethanol group.  The procedural separation between seeking (lever-
pressing) and consumption was then established.  Initially, following completion of a 
single response requirement (4 lever-presses) access to a sipper tube was provided for 20 
uninterrupted minutes.  Over two weeks, the response requirement was increased from 4 
to 10, and then the response requirement of 10 was maintained for two additional weeks 
(Figure 1). 
 
Treatment Schedule and Test Sessions 
A 4-week consummatory testing phase was initiated in which all animals got one 
IP injection of either vehicle or one of three doses of prazosin (0.5, 1.0, 1.5 mg/kg) in a 
balanced/random design on one day each week (the other four days were normal, no 
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injection days).  IP injections were given 30 minutes prior to the start of the operant 
session in which animals lever-pressed (i.e., the response requirement was reduced to 1 
on testing days so that animals were more likely to obtain access to the reinforcer) to gain 
unlimited access to ethanol or sucrose for a 20 minute period.  Following the 
consummatory phase, three weeks of no treatment began to ramp the animals up from a 
RR10 to an RR20.  Next, a 4-week appetitive phase began in which the same type of drug 
treatments each preceded a single, weekly (Thursdays) extinction session such that the 
animals could still press the lever for the entire 20 minute session but never get 
reinforced.  Animals were injected on Tuesday of the same week with vehicle (1 ml/kg 
BW) to control for the possibility of injections predicting an extinction session.  These 
vehicle injections were accompanied by reinforced operant sessions.  The other three 
days of the week were normal, injection-free reinforced sessions.   
 
Blood Ethanol Concentration (BEC) Determination 
 Following all prazosin treatments and immediately following the final 20 minutes 
of ethanol access, blood samples were collected (100 µl) into heparinized capillary tubes 
from a nick to the tip of the tail while the rats were restrained briefly for a maximum of 
2-4 minutes.  Samples were stored on ice during collection and then immediately 
centrifuged and a 5 µl sample of plasma was analyzed using the AMI Analyzer (Analox 
Instruments, Lunenburg, MA, USA).  Ethanol concentration was determined with an 
amperometric oxygen electrode that measures oxygen consumption during the enzymatic 
oxidation of alcohol to acetaldehyde. 
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Data Analyses and Statistics 
Dependent measures for the consummatory testing phase were total intake of 
sucrose and ethanol determined from the change in fluid volume in the graduated 
cylinder sipper tube and g/kg intake were calculated from the intake volume and daily 
body weight measures.  Total lever-presses, licks, and cumulative records of responding 
were recorded for each session.  Latency to lick in seconds was also recorded for each 
daily session.  Dependent measures for the appetitive testing phase were total number of 
lever-presses and latency in seconds to lever-press for each appetitive session.  
Data were analyzed using two-way within-subject repeated measures analysis of 
variance (RM ANOVA; reinforcer and dose as the main variables) and post hoc 
comparisons were performed using Student-Newman-Keuls.  In addition, t-tests were 
used to compare the alcohol and sucrose groups for all responses in the vehicle condition 
to further assess “baseline” responding.  Percent change from baseline was calculated by 
subtracting intake/responding during prazosin administration from vehicle 
intake/responding and dividing this difference by vehicle intake/responding.  Percent 
change data were analyzed using two-way repeated measures ANOVA and post hoc 
comparisons were performed using Student-Newman-Keuls.  All analyses were 
conducted using the SigmaStat 3.5 program (Systat Software, Inc., Chicago, IL) with 
significance accepted at p < 0.05.  Data are presented as mean ± SEM. 
 
Results 
For the Consummatory Phase only, one rat was dropped from the analyses 
(ethanol group) for failure to respond on the vehicle injection day (i.e. failure to provide a 
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reliable control response) due to difficulty with the injection procedure (broken toe nail).  
 On the final day of operant sessions, BECs ranged from 20.9 to 102.6 with an 
average BEC of 54.9 (± 10.3), as measured at the end of the 20 minute self-
administration period.  Vehicle-treated rats that were lever-pressing for ethanol averaged 
69.7 responses and 0.90 g/kg of ethanol consumed.  Vehicle-treated rats that were lever-
pressing for sucrose averaged 104.7 responses and 1.10 g/kg sucrose consumed.  Figure 2 
shows mean (± SEM) reinforcer-seeking (lever-presses in 20 min) on the appetitive 
testing days for the sucrose-reinforced (white bars) and ethanol-reinforced (black bars) 
groups over one of three doses of prazosin (0.5, 1.0, 1.5 mg/kg) or vehicle (zero) 
treatments (-30 min).  A repeated measures ANOVA indicated that there was a main 
effect of treatment [F (3,39)=8.3, p ≤ 0.001] with post hoc analyses showing that all 
prazosin doses differed from control (*).  There was no effect of reinforcer and no 
reinforcer by dose interaction.  A follow up analysis of percent change from baseline on 
responding for ethanol- and sucrose-reinforced groups confirmed that there was no main 
effect of  reinforcer (p=0.180) or a reinforcer by dose interaction (p=0.492).  With regard 
to consumption, Figure 3 shows mean (± SEM) total reinforcer intake  (g/kg over 20 min) 
on consummatory testing days for the sucrose-reinforced (white bars) and ethanol-
reinforced (black bars) groups over one of three doses of prazosin (0.5, 1.0, 1.5 mg/kg) or 
vehicle (zero) treatments (-30 min).  A repeated measures ANOVA indicated that there 
was a main effect of treatment [F(3,36)=7.9, p ≤ 0.001] with post hoc analyses showing 
that only the high dose of prazosin differed from control (*).   
Further, prazosin (1.5 mg/kg) increased the latency to lever-press and to lick for 
ethanol but not for sucrose.  Figures 4 and 5 show mean (± SEM) latency (seconds) to 
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first lever-press and first lick on appetitive and consummatory testing days, respectively. 
Sucrose-reinforced (white bars) and ethanol-reinforced (black bars) groups over control 
and prazosin treatments (-30 min) are shown.  For both measures, a repeated measures 
ANOVA indicated an interaction effect such that in the ethanol group only, the high dose 
of prazosin increased the time to first lever-press [F(3,39)=4.6, p ≤ 0.01] and first lick 
[F(3,39)=4.6, p ≤ 0.01].  Because of the high variability of these responses and the 
absence of a response in some cases (assigned 1200 sec), a Mann-Whitney Rank Sum test 
at the high dose confirmed these findings (*) (Median values - Appetitive: sucrose 24.4, 
ethanol 182.6; Consummatory: sucrose 2.9, ethanol 656.8).   
 
Discussion 
The purpose of experiment 1 was to extend previous findings and evaluate the 
role of prazosin, an α1-adrenergic receptor antagonist, on distinct ethanol-seeking and 
intake behaviors in P rats consuming binge-like levels of ethanol.  Overall, prazosin, 
administered acutely, decreased ethanol consumption at the highest dose, whereas 
ethanol-seeking was attenuated at all doses.  These findings are consistent with and 
extend those of Walker et al. (2008) where the high dose of prazosin (2.0 mg/kg) was 
necessary to attenuate a combined seeking/drinking response in non-dependent Wistar 
rats.  These findings also extend those of Rasmussen et al. (2009) where prazosin (1.0, 
1.5, 2.0 mg/kg) decreased ethanol intake, with the 0.5 mg/kg dose becoming effective 
only after three consecutive days of treatment.  Further, latencies to first lick (on 
consummatory test days) and lever-press (on appetitive test days) were increased at the 
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highest dose in the ethanol group indicating a decrease in motivation to seek and obtain 
ethanol.   
Generally, prazosin decreased sucrose-seeking and consumption at the same doses 
required to decrease ethanol-seeking and intake.  However, there are indications that the 
effects of prazosin were selective for ethanol.  The highest dose of prazosin decreased 
ethanol-seeking and drinking by 76% and 67%, respectively, whereas sucrose-seeking 
and drinking was decreased by only 44% and 39%, respectively.  Additionally, the 
highest dose of prazosin increased the latency to first lever-press and to first lick in the 
ethanol group only suggesting a decrease in motivation to obtain ethanol.  The fact that 
latencies to first lever-press or lick for sucrose were not altered by prazosin indicates that 
the increased latencies for ethanol-seeking and drinking were not due to prazosin-induced 
motor-impairment or malaise.  Also, latency measures were taken during extinction 
sessions when no ethanol was available (on appetitive test days) or up until the first lick 
(on consummatory test days), and therefore the increased latencies to lever-press and lick 
were not due to the pharmacological properties of ethanol.  These findings suggest that 
prazosin may be an effective pharmacotherapeutic drug for treating alcohol use disorders, 
and possibly a treatment that targets the motivation to initiate episodes of heavy ethanol 
consumption.  Since any drug given to treat alcohol abuse would not be given acutely, it 
is necessary to look at the effects of chronic prazosin treatment on reinforcer-seeking and 
intake.
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EXPERIMENT 2 
Introduction 
Clinically, it is important to examine prazosin chronically as any treatment for 
alcohol abuse would be administered over multiple days.  Additionally, chronic studies 
looking at the effects of other treatments for alcohol abuse (e.g. naltrexone) using 
repeated dosing should be examined in order to better understand a chronic dosing 
regimen.  Chronic dosing of naltrexone has been found to decrease the palatability of 
ethanol (Hill et al., 2010) and repeated dosing of naltrexone, using identical procedures as 
Experiment 2, has been found to dose dependently decrease ethanol and sucrose intake 
and decrease seeking of ethanol only (Czachowski and DeLory, 2002).  Here, repeated 
dosing of a drug could lead to reinforcer devaluation over time due to a decrease in 
motivation caused by repeated drug/reinforcer pairings.  In fact, Czachowski and DeLory 
(2002) suggest that the decrement in responding for ethanol after chronic naltrexone 
treatment may be due to reinforcer devaluation.  However, extinction of the reinforcing 
properties of a reinforcer and conditioned taste aversion could also account for a 
decrement in intake and responding with repeated dosing of any drug treatment.  
Important to Experiment 2 is the fact that repeated dosing of naltrexone over 14 days did 
not lead to tolerance or sensitivity to the drug (Czachowski and DeLory, 2002).  Also, 
previous studies of acute naltrexone administration have shown non-reinforcer specific 
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(ethanol vs. sucrose) effects on consumption (Stromberg et al., 2002) while chronically, 
ethanol consumption was decreased to a slightly greater degree than for sucrose 
(Czachowski and DeLory, 2002).  Similarly, acute administration of prazosin in 
Experiment 1 decreased both ethanol- and sucrose-seeking and intake, with a slightly 
greater decrement in responding and consumption in the ethanol-reinforced group.  
Therefore, chronic prazosin treatment, using the same paradigm and identical methods to 
Czachowski and DeLory (2002), should be tested for its specific effects on ethanol- and 
sucrose-seeking and intake in the P rat. 
Thus, the aims of Experiment 2 were to expand on the data from Experiment 1 
and assess the effects of chronic prazosin treatment on ethanol- and sucrose-seeking and 
consumption in the ‘sipper-tube’ paradigm.  Although latency data in Experiment 1 
showed that drug-induced motor impairment or malaise was not an issue, animals still 
appeared to be somewhat sedated by visual observation.  Therefore, the chronic study 
utilized a lower dose range to minimize any sedative effect on the subjects while ideally 
maintaining the pharmacotherapeutic effect of the drug.  This lower dose range has been 
used in previous studies of prazosin effects on ethanol drinking (Rasmussen et al., 2009; 
Walker et al., 2008).  Moreover, while acute treatment of prazosin yielded non-reinforcer 
specific results, Experiment 2 aimed to determine if chronic treatment of prazosin yields 
reinforcer specific effects for ethanol and if these effects work by decreasing 
consumption versus seeking of ethanol or both.  Experiment 2 also aimed to determine 
whether prazosin is an ‘anti-craving’ drug since acute administration of prazosin (1.5 
mg/kg) increases the latencies to lever-press and to lick indicating a decrease in the 
motivation to initiate ethanol drinking (reduction in craving), or whether chronic prazosin 
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treatment works by blocking the reinforcing properties of ethanol when the animal has 
been drinking during treatment.
Furthermore, this study aimed to determine if an animal would seek (in lever-
presses) ethanol once the animal has been without treatment (i.e., the prazosin/ethanol 
pairings) for three days.  Essentially, the paradigm seeks to find if chronic prazosin 
treatment attenuates seeking once drug treatment stops.  Finally, Experiment 2 aimed to 
determine if there is tolerance to prazosin when administered chronically and at what 
time-point during administration tolerance occurred or if sensitivity to the drug is seen 
after chronic treatment.   
Based on previous literature and findings from Experiment 1, it was hypothesized 
that chronic prazosin treatment would be effective as a pharamacotherapeutic agent for 
the treatment of alcohol use disorders.  Specifically, it was hypothesized that chronic 
prazosin would decrease ethanol-seeking and intake to a greater degree than for sucrose 
and that lower doses would become more effective with further days of treatment.  Again, 
this is based on findings that during a 5- day prazosin treatment regimen the lowest dose 
of prazosin became effective after the second day and the highest doses of prazosin 
became less effective after the third day of treatment (Rasmussen et al., 2009).  
Additionally, it was hypothesized that latency to lever-press and lick would be increased 
for ethanol based on findings from Experiment 1, indicating a decrease in motivation to 
respond for ethanol.  Furthermore, based on the non-reinforcer specific findings of 
Experiment 1, it was hypothesized that if prazosin were to decrease sucrose-seeking and 
intake it would be at the highest doses of prazosin and would not affect latencies to lick 
or lever-press. 
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Materials and Methods 
Subjects 
 Twenty-four adult male P rats from the sixty-ninth generation of selective 
breeding served as subjects and were randomly divided into two groups; an ethanol 
reinforced group and a sucrose reinforced group (n=12/group).  Their daily handling and 
weighing, housing, and feeding conditions were identical to Experiment 1.   
 
Apparatus 
 
 Daily sessions were conducted in operant chambers identical to Experiment 1 and 
solutions became available in a manner identical to Experiment 1.    
 
 
Drugs 
 
 Ethanol, sucrose, and sucrose/ethanol solutions were prepared identically to 
Experiment 1.  Prazosin hydrochloride (Sigma-Aldrich, Inc., St. Louis, MO; Tocris 
Bioscience, Ellisville, MO) was dissolved in sterile water at 1 ml/kg BW.  Prazosin was 
injected IP in a dose of 0.0, 0.25, 0.5, or 1.0 mg/kg BW, 30 minutes prior to the start of 
the operant sessions.   
 
 
Training and Ethanol Initiation 
 
 Training and ethanol initiation were identical to Experiment 1 except final 
solutions reached 1% sucrose for the sucrose group and 10% ethanol for the ethanol 
group.  1% sucrose was used in this study as opposed to 2% sucrose (used in 
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Experiment 1) to best equate intake volumes with 10% ethanol.  After establishing stable 
responding for the reinforcer, the procedural separation between seeking (lever-pressing) 
and consumption was established.  Initially, following completion of a single response 
requirement (4 lever-presses) access to a sipper tube was provided for 20 minutes.  The 
response requirement was then increased from an RR 4 to an RR20, and this training 
phase was completed by the end of week 6 (see Figure 6). 
 
 
Treatment Schedule and Test Sessions 
 
 Daily session cycles of drug (3 weeks/ 14 sessions from a Tuesday to Friday) or 
vehicle (2 weeks/ 9 sessions from a Tuesday to Friday) treatment were alternated per 
drug dose for a total of three drug doses per rat.  Like Experiment 1, during operant 
sessions the response requirement was decreased to an RR1 to ensure that all subjects 
gained access to the reinforcing solution (10% ethanol or 1% sucrose).  At the end of 
each cycle, a single, non-reinforced extinction session was conducted on a Monday 
following two days of no injections or reinforcer access.  Extinction sessions consisted of 
twenty minutes of access to the lever with no presentation of the sipper tube.  Solutions 
were present in the sipper tube to control for scent cues.  Unlike Experiment 1, prazosin 
was not ‘on-board’ during each extinction session.  The response requirement was then 
gradually increased again to an RR20 for the remainder of that week (no injections) to 
ensure that subjects continued to respond at an RR20 (i.e. that the prolonged exposure to 
the RR1 schedule did not cause a decrement in responding) and then the next drug dose 
cycle was initiated.  That is, a 14 day drug cycle was followed by an extinction session 
(Monday after cycle ends), with the remainder of the week consisting of increasing the 
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RR to 20.  Then, a 9-day sterile water cycle began followed by an extinction session 
(Monday after cycle ends) with the remainder of the week consisting of increasing the 
RR to 20.  This process then repeated itself until all three drug doses were administered 
to each rat.  The extinction session at the end of each cycle is used to assess ethanol or 
sucrose seeking after chronic administration of the drug or vehicle.  This is the appetitive 
portion of the experiment and, again, was conducted with no drug on board and when no 
reinforcer could be obtained.  Once more, three doses of prazosin, 0.25, 0.5, and 1.0 
mg/kg, were used in a balanced/random order design by subject across the three dosing 
cycles with a corresponding sterile water cycle paired to each dose (a total of three drug 
cycles, one for each dose, and two intervening sterile water cycles) (See Figure 6 for a 
timeline of each drug cycle and vehicle cycle and Table 1 for daily within session 
response requirements during each cycle).   
 
BEC Determination 
 
 BEC determination was similar to Experiment 1.  BECs were collected at the end 
of the last drug dose cycle at the end of a 20 minute drinking session when no drug was 
on board.   
 
Data Analyses and Statistics 
  Dependent measures for the consummatory and appetitive testing were identical 
to Experiment 1.  The ethanol group and the sucrose group were analyzed separately 
using repeated measures ANOVAs and post hoc comparisons were performed using the 
Student-Newman-Keuls method when appropriate.  Sterile water treatment data were 
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collapsed for each subject when possible as determined by a repeated measures ANOVA.  
Dose (0.0, 0.25, 0.5, 1.0 mg/kg prazosin) and Day were the main factors over the first 
nine days.  In addition, mean intake over the nine sterile water or 14- drug day treatments 
were analyzed with dose as the main factor.  For appetitive data, dose was the main 
factor.  Percent change from baseline was calculated and analyzed identically to 
Experiment 1. 
 
Results 
All groups started with twelve subjects, and a total of one rat was dropped from 
the initial 24 animals.  One animal was dropped from the analyses (sucrose group) for 
failure to respond on the first two days of testing due to difficulty with the injection 
procedure (broken toe nails).  There were no significant differences of intake between the 
two vehicle control periods (9 days of vehicle injections after each drug cycle) for 
ethanol- and sucrose-reinforced groups (p=0.08 and p=0.29, respectively).  Likewise, 
there were no significant differences in responding for ethanol or sucrose between vehicle 
cycles 1 and 2 (p=.915), therefore, vehicle control periods were collapsed and a third 
vehicle cycle was not initiated.   
 On the final day of operant sessions, BECs ranged from 28.1 to 97.5 with an 
average BEC of 56 (± 6), as measured at the end of the 20 minute self-administration 
period.  In the ethanol-reinforced group, analysis of ethanol intake (g/kg) following 
vehicle or prazosin (Figure 7) over days 1-9 showed that there was a main effect of day 
[F(3, 264)=4.45, p<0.001].  Post hoc analyses indicated that the effect of day was due to 
an increase in intake on day 5 (day 5 vs. days 2, 3, 6, 7, and 8). There was no main effect 
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of dose and no day by dose interaction.  Analysis of total mean ethanol intake collapsed 
over all days (days 1-14) indicated that there was no main effect of dose (Figure 8).   
 In the sucrose-reinforced group, analysis of sucrose intake (g/kg) following 
vehicle or prazosin (Figure 9) over days 1-9 showed that there was a main effect of dose 
[F(3,240)=5.1, p=0.006], with post hoc analyses indicating that the low and medium dose 
decreased intake relative to both vehicle treatment and the high dose of prazosin.  There 
was also a main effect of day [F(8,240)=10.96, p<0.001].  Post hoc analyses indicated 
that this was due to slightly higher intakes over day 1 (day 1 vs. days 2-9) and day 2 (day 
2 vs. days 7, 8, and 9).  There was no day by dose interaction.  Analysis of total mean 
sucrose intake collapsed over all days showed a main effect of dose [F(3,30)=5.71, 
p=0.003], and post hoc analyses showed that all three doses of prazosin decreased intake 
as compared to vehicle (Figure 10).  An analysis of percent change of baseline on intake 
for ethanol- and sucrose-reinforced groups confirmed that there was not a main effect of 
reinforcer (p=0.600), dose (p=0.790), and no reinforcer by dose interaction (p=0.558).   
 Ethanol-seeking and sucrose-seeking following sterile water and prazosin 
treatments were assessed using extinction responding.  There was a main effect of dose 
[F(3, 63)=5.302, p=0.003], with post hoc analyses indicating that the low and high dose 
of prazosin decreased seeking relative to vehicle.  There was no main effect of reinforcer 
and no reinforcer by dose interaction (Figure 11).  An analysis of percent change of 
baseline on responding for ethanol- and sucrose-reinforced groups indicate that there was 
not a main effect of reinforcer (p=0.556), dose (p=0.084), and no reinforcer by dose 
interaction (p=0.379).   
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 With regard to latency, in the ethanol-reinforced group, analyses of latency to lick 
(on consummatory testing days) following vehicle or prazosin (Figure 12) over days 1-9 
and total mean latencies to lick collapsed over all days (1-14) indicated that there was no 
effect of dose, day, and no day by dose interaction.  Likewise, analyses of latency to 
lever-press (on appetitive testing days) showed no main effect (Figure 13).  In the 
sucrose-reinforced group, analysis of latency to lick (on consummatory testing days) 
following vehicle or prazosin (Figure 14) over days 1-9 showed that there was a main 
effect of day [F(8,240)=2.29, p=0.029], with post hoc analyses indicating that day 1 was 
significantly different from all other days.  There was no main effect of dose and no day 
by dose interaction.  Analysis of total mean latencies to lick collapsed over all days (1-
14) indicated that there was no main effect of dose.  Analysis of latency to lever-press 
(Figure 13) (on appetitive testing days) showed a main effect of dose [F(3,30)=4.32, 
p=0.012], with post hoc analyses indicating that the lowest dose of prazosin increased the 
latency to lever-press as compared to vehicle.  Further, in the ethanol- and sucrose-
reinforced groups, analysis of day 1 intakes following vehicle or prazosin showed a main 
effect of reinforcer [F(1,63)=34.2, p<0.001] with greater intake of sucrose overall, but no 
interaction between reinforcer and dose.  
 
Discussion 
         The purpose of Experiment 2 was to expand on the findings from Experiment 1 and 
evaluate the role of chronic prazosin treatment on reinforcer-seeking and self-
administration.   Overall, chronic prazosin treatment decreased reinforcer seeking at the 
lowest and highest dose, whereas ethanol consumption was not affected by prazosin.  
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Conversely, in the sucrose-reinforced group, prazosin at the lowest doses, 0.25 mg/kg and 
0.5 mg/kg, decreased intake when looking at the 9-day dosing regimen.  However, 
prazosin attenuated sucrose intake at all doses tested (0.25, 0.5, 1.0 mg/kg) when looking 
at mean intakes over 14 days.  Latency to first lick was only significant on the first day of 
treatment and the lowest dose of prazosin increased the latency to lever-press during 
appetitive extinction sessions for the sucrose group only.  There was no indication of 
tolerance to treatment effects over the 9 or 14-day dosing regimens and no indication of 
prazosin-induced motor impairment or malaise as evidenced by the lack of effects on 
latency to lick or respond in the ethanol group. 
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GENERAL DISCUSSION 
 
Again, the ‘sipper-tube’ paradigm used in the present study made it possible to 
determine whether prazosin treatment had any differential effects on reinforcer-seeking 
and drinking behaviors in the P rat.  This was ensured by the use of a low response 
requirement for intake assessment as well as single extinction sessions to assess seeking.  
Because the present investigations included a sucrose-reinforced control group, a 
comparison between prazosin treatment effects, specific behaviors (appetitive versus 
consummatory) targeted by prazosin treatment, and reinforcer selectivity of prazosin 
could be determined. 
Important to the present findings is the fact that these are the first two experiments 
to use a control reinforcer (sucrose) when examining the effects of prazosin on seeking 
and consumption behaviors.  Water intake has been assessed in non-thirsty animals being 
treating with prazosin (Rasmussen et al., 2009; Walker et al., 2008).  Water intake was 
examined in a 2-hour, 2-bottle choice (ethanol versus water) paradigm looking at the 
effects of prazosin on free-access drinking (Rasmussen et al., 1009).  This study found no 
evidence of a decrease in water intake in a 2-day and subsequent 5-day treatment of 
prazosin (Rasmussen et al., 2009).  This is also consistent with findings reporting no 
effect on water intake during acute withdrawal of alcohol-dependent rats being treated 
with prazosin (Walker et al., 2008).  Due to the non-reinforcer specific effects of prazosin 
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on seeking and drinking in Experiment 1 and because prazosin attenuated reinforcer-
seeking, sucrose intake, and latency to lever-press for sucrose in Experiment 2, the drug 
may work to decrease the reinforcing properties of oral reinforcers in general.  
Additionally, prazosin has been shown to reduce the reinforcing properties of nicotine 
and heroin self-administration (Bruijnzeel et al., 2010; Forget et al., 2010; Greenwell et 
al., 2009) and prazosin has been found to decrease yohimbine-induced reinstatement of 
food seeking (Le et al., 2011).  These findings, together with results from Experiment 1 
and Experiment 2, suggest that prazosin may work by suppressing the reinforcing 
properties of oral reinforcers (ethanol, sucrose, food) and other drugs (nicotine, heroin).  
Therefore, inhibition of central adrenergic activity by prazosin may, in fact, attenuate 
seeking and intake behaviors universally.   
Experiment 2 tested seeking three days after prazosin treatment and three days 
after ethanol- or sucrose-reinforced sessions.  This is unlike Experiment 1 in that 
Experiment 1 examined reinforcer-seeking with prazosin on board.  Overall, there was a 
decreased tendency to seek the reinforcers during appetitive sessions at the lowest dose of 
prazosin (0.25 mg/kg) and highest dose of prazosin (1.0 mg/kg) compared to vehicle.  
Since subjects had no prazosin on board at the time of these extinction sessions, the 
decreases in responding indicate that the rats must have learned something about the 
prazosin experience that attenuated their reinforcer-seeking response three days post-
treatment.  Specifically, it is likely that rats learned to devalue ethanol and sucrose caused 
by repeated and chronic prazosin/reinforcer pairings during reinforced sessions.  This 
indicates that prazosin may work by decreasing motivation to seek ethanol and sucrose 
which is in agreement with Experiment 1 in that all doses of prazosin in Experiment 1 
30 
 
 
attenuated ethanol- and sucrose-seeking.  It is unlikely that the decrement in responding 
is due to a conditioned taste aversion of the reinforcer when prazosin is on board because 
intakes were not affected in the ethanol-reinforced group.  Likewise, it is improbable that 
prazosin/reinforcer pairings extinguished the rewarding properties of each reinforcer 
because, again, ethanol intake was not affected by prazosin.  It is unlikely that prazosin 
produced a general malaise over treatment days that interfered with seeking because 
latencies to respond were not affected in the ethanol-reinforced group.  It is also unlikely 
that prazosin had general effects on arousal because prazosin’s effects on latency to 
respond were specific to sucrose. 
With regard to intake in the ethanol-reinforced group, although a decrease in 
intake by prazosin was not observed, an increase in ethanol consumption was observed 
on day 5 (Monday following three days of no treatment).  Figure 7 suggests that, even 
though there was no day by dose interaction and no day 10 vehicle treatment for 
comparison, there was a rebound effect on ethanol intake after the weekends (72 hours 
without ethanol access and no prazosin treatment).  These findings indicate that 
individuals taking prazosin to treat alcohol abuse must take this medication consecutively 
in order for a decrease in alcohol consumption to occur.  This should be addressed in 
future projects by testing chronic prazosin treatment seven days per week for three 
consecutive weeks instead of five days per week for three consecutive weeks as seen in 
the Experiment 2.  Notable is the observation that ethanol intake was variable for vehicle 
treatment and all three doses of prazosin.  Figure 7 and Figure 8 show that ethanol intake 
barely exceeded 0.7 g/kg during vehicle treatment.  This is in sharp contrast to 
Experiment 1 where P rats were drinking approximately 0.9 g/kg of ethanol at vehicle 
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and with previous findings suggesting that the P rat drink excessive amounts of ethanol 
(Bell et al., 2006; Li et al., 1987).  Figure 7 shows ethanol intake 14 days prior to the start 
of drug testing.  During these 14 days (normal reinforced operant sessions without 
prazosin injections), ethanol intake only exceeded 0.8 g/kg three times with an average 
intake over all 14 days of 0.77 g/kg.  If ethanol intake were higher in Experiment 2, then 
the effects of chronic prazosin treatment may have been much greater.   
Additionally, chronic administration of prazosin decreased sucrose consumption.  
This is consistent with Experiment 1, which utilized a slightly higher dosing range 
(0.5 -1.5 mg/kg), in that the highest dose of prazosin was able to decrease sucrose 
consumption.  However, lower doses decreased sucrose intake in Experiment 2 than 
required to decrease consumption in Experiment 1 indicating that prazosin is effective at 
decreasing the reinforcing properties of sucrose at lower doses when administered 
chronically.  Further, the highest dose of prazosin was not effective in decreasing sucrose 
intake when examining intake over nine days.  However, sucrose consumption decreased 
at the highest dose of prazosin when assessing intake over a 14 day period.  This 
indicates that animals become more sensitive to the highest dose of prazosin with further 
days of treatment.  Also, day 1 and day 2 of treatment resulted in higher sucrose intakes 
overall as compared to the other 12 days of treatment.  This could suggest, again, that 
prazosin becomes more effective at decreasing sucrose consumption with further days of 
treatment.  However, Figure 9 suggests that this is highly unlikely because intake during 
vehicle treatment was high on day 1 and, on day 2, intake decreased below the medium 
and high doses of prazosin before becoming stable.  The fact that sucrose intake was 
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decreased by all doses of prazosin does not indicate that any neuroadaptation was caused 
by prazosin in subjects drinking sucrose.    
 Chronic prazosin treatment also increased the latency to lick on the first day of 
treatment in the sucrose group only.  The highest dose and medium dose of prazosin 
increased the latency to first lick in consummatory sessions over day 1-9.  One animal 
(sucrose group) was dropped from Experiment 2 for failure to respond for multiple days 
due to multiple broken toenails.  However, two other animals in the sucrose group failed 
to respond and took longer to respond on the first day of injections only due to difficulty 
with the injection procedure (i.e. one animal bit the plastic carrier cart and another animal 
broke one toenail).  Therefore, the increased latency to lick in the sucrose group on the 
first day may be more of a reflection of first day difficulties with the injection procedure 
or injuries associated with the first day.  These findings are inconsistent with Experiment 
1 in which latency to lick was increased in the ethanol group only at the highest dose 
tested (1.5 mg/kg) where only one animal (ethanol group) was dropped for failure to 
respond on the vehicle injection day (i.e. failure to provide a reliable control response).  
Perhaps latency to first lick was not increased in the ethanol group in Experiment 2 
because the dose range used was slightly lower than Experiment 1.  The dose that 
increased the latency to lick and lever-press in the ethanol group (1.5 mg/kg) in 
Experiment 1was not used in Experiment 2 (0.25 - 1.0 mg/kg).   
 Similarly, chronic prazosin treatment increased the latency to first lever-press in 
the sucrose group only.  The lowest dose of prazosin increased the latency to lever-press 
as compared to vehicle during appetitive testing sessions when no prazosin was on-board 
and no sucrose could be obtained (three days after consecutive prazosin treatment).  The 
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present findings indicate that prazosin, when administered chronically, decreases the 
motivation to initiate sucrose-seeking behaviors.  Again, this is inconsistent with findings 
from Experiment 1 in which latency to lever-press was increased by the highest dose 
(1.5 mg/kg) in the ethanol group only.  Perhaps, this discrepancy could, again, be 
attributed to the lower dose range utilized in Experiment 2.  Lower doses (0.25 mg/kg) 
than used in Experiment 1 increased latency to lever-press in the sucrose group in 
Experiment 2.  Also, perhaps, subjects drinking ethanol need a higher dose than those 
utilized in Experiment 2 in order to decrease their motivation to initiate and engage in 
ethanol consumption such as the 1.5 mg/kg dose used in Experiment 1.  Again, it is 
unlikely that the increased latency to lick and lever-press were due to prazosin-induced 
motor impairment or malaise because latencies were not increased in the ethanol-
reinforced group.   
 Overall, the results of Experiment 1 and Experiment 2 are consistent with and 
extend previous literature on the effects of prazosin, at similar doses, route and timing of 
administration, on ethanol seeking and self-administration. Experiment 1 is consistent 
with that of Walker et al. (2008) where prazosin blocked ethanol dependence-induced 
operant responding in Wistar rats and that of Rasmussen et al. (2009) where prazosin 
decreased voluntary ethanol consumption in the P rat.  It also extends findings that 
alcohol-dependent men reported fewer drinks per week and fewer drinking days per week 
while being treated with prazosin (Simpson et al., 2009).  Experiment 2 is consistent with 
Experiment 1 in that seeking was attenuated at the lowest dose  and highest doses of 
prazosin.  Experiment 1 and Experiment 2 are consistent with each other in that neither 
study found prazosin’s effects to be exclusive to one reinforcer.  It is problematic that 
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prazosin was not reinforcer-specific and could be an indication that prazosin works by 
devaluing oral reinforcers overall.  However, the present findings are limited to male, P 
rats, and other rat strains as well as females should be examined in order to assess 
prazosin treatment effects on different rodent populations. 
 The current results suggest that the noradrenergic system plays a key role in 
maintaining ethanol- and sucrose-seeking and drinking in animals selectively bred for 
high alcohol drinking.  Previous findings suggest that noradrenergic signaling may 
modulate ethanol self-administration in that depletion of brain levels of norepinephrine 
results in an attenuation of ethanol self-administration in Sprague-Dawley rats (Davis et 
al., 1978) which is consistent with the central actions of prazosin.  Similarly, lesions of 
noradrenergic neurons were found to decrease ethanol intake (Brown and Amit, 1977).  
Important to the present studies, excessive noradrenergic signaling is characteristic of 
patients with PTSD and comorbid alcohol abuse (Raskind et al., 2003).  These patients 
show signs of heightened arousal (Saladin et al., 1995) or hyperexcitability, which is also 
seen in P rats exhibiting a greater startle response relative to their non-preferring 
counterparts (Chester et al., 2004).  This suggests that rodents genetically bred for 
alcohol-preference may display excessive noradrenergic signaling and prazosin, an α1-
adrenergic antagonist, can suppress this noradrenergic activation thereby decreasing the 
reinforcing properties of ethanol.  However, prazosin also decreases the reinforcing 
properties of nicotine and heroin, and decreases yohimbine-induced reinstatement of food 
seeking (Bruijnzeel et al., 2010; Forget et al., 2010; Greenwell et al., 2009; Le et al., 
2011) and may work on attenuating seeking and intake behaviors in general.   
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Future Directions and Conclusions  
In the future, these findings could be extended to different rat strains to see if 
prazosin has an effect in other rodents genetically bred for alcohol drinking such as the 
HADs as well as rat strains that are not bred for alcohol preference such as the Long 
Evans.  This could lead to treatment approaches in alcoholics seeking treatment and in 
alcohol abusers that seek to control their intake.  It would also be beneficial to look at 
dosing strategies.   Higher doses of prazosin appear to decrease the intake of oral 
reinforcers as evidenced by Experiment 1 and Experiment 2, whereas lower doses 
decreased reinforcer-seeking.  Further, enriched environments have been shown to 
decrease ethanol drinking, preference, and motivation to obtain ethanol in P rats 
compared to those in an impoverished environment (Deehan et al., 2011).  Since prazosin 
has been observed to decrease alcohol drinking in patients with PTSD as well as to 
alleviate their distressing nightmares, it would be interesting to look at ethanol-seeking 
and intake in rats treated with prazosin when the environment of the subject is 
manipulated i.e. enriched, normal, or impoverished (stressful context).  
 Additionally, prazosin was found to decrease elevations in brain reward 
thresholds associated with nicotine withdrawal while the α2-adrenergic receptor agonist 
clonidine and the β-adrenergic receptor antagonist propranolol attenuated somatic signs 
associated with nicotine withdrawal (Bruijnzeel et al., 2010).  Future studies should look 
at the combination treatment of prazosin and clonidine or prazosin and propranolol on 
their combined efficacy in attenuating ethanol-seeking and consumption as well as the 
withdrawal symptoms of alcohol abuse.  Similarly, a combined prazosin and clozapine, 
an atypical antipsychotic, treatment could be effective in reducing ethanol-seeking and 
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consumption while not devaluing other oral reinforcers, such as sucrose.  Clozapine has 
been found to increase reward evaluation of sucrose (Galistu et al., 2011), and attenuate 
ethanol withdrawal symptoms in Wistar rats (Kayir and Uzbay, 2008).  Further, it has 
been shown that chronic treatment with clozapine in rodents decreases ethanol drinking 
in the continuous access paradigm (Chau et al., 2010; Green et al., 2004).  Future studies 
could also examine the effects of injecting prazosin directly into the brain.  Alpha1-
adrenergic receptors are located ubiquitously throughout the brain (Pieribone et al., 1994) 
thus central administration of prazosin may further extend the effects on ethanol-seeking 
and intake observed when the drug is administered peripherally.  Finally, doxazosin, an 
α1-adrenergic receptor antagonist, is used to treat hypertension, like prazosin, but has a 
longer half life (11 hours) (Elliott et al., 1982).  Future studies could examine the effects 
of doxazosin on ethanol-seeking and consumption in the same operant paradigm used in 
the present studies.  
 In summary, acute prazosin administration was able to decrease reinforcer-
seeking and intake and decrease the motivation to initiate ethanol-seeking.  Chronic 
treatment of prazosin was able to decrease reinforcer-seeking.  However, sucrose intake 
was attenuated by chronic prazosin treatment and, perhaps, the motivation to initiate 
sucrose-seeking was decreased.  The operant model utilized, one that separately assesses 
seeking and drinking behaviors, revealed that prazosin, an α1-adrenergic receptor 
antagonist, may not be reinforcer specific.  If prazosin is given as treatment for alcohol 
use disorders then patients should be advised that prazosin may affect their seeking and 
intake of other reinforcers. 
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Table 1. Daily within session descriptions for Experiment 2. An ethanol-reinforced and a sucrose-reinforced 
group underwent the following conditions for the indicated number of days (more detailed descriptions are 
given in ‘Materials and Methods’ of Experiment 2.
M  T  W  Th  F  M  T  W  Th  F  M  T  W  Th  F 
Training Week 
6    RR20  RR20  RR20  RR20  RR20                     
Drug Cycle 1 
(14 days)   
EXT 
(baseline)  RR1  RR1  RR1  RR1  RR1  RR1  RR1  RR1  RR1  RR1  RR1  RR1  RR1  RR1 
DC1 EXT & 
↑RR   
EXT 
(DC1)  RR5  RR10  RR15  RR20                     
Vehicle Cycle 1 
(9 days)    RR20  RR1  RR1  RR1  RR1  RR1  RR1  RR1  RR1  RR1           
VC1 EXT & 
↑RR   
EXT 
(VC1)  RR5  RR10  RR15  RR20                     
Drug Cycle 2 
(14 days)    RR20  RR1  RR1  RR1  RR1  RR1  RR1  RR1  RR1  RR1  RR1  RR1  RR1  RR1  RR1 
DC2 EXT & 
↑RR   
EXT 
(DC2)  RR5  RR10  RR15  RR20                     
Vehicle Cycle 2 
(9 days)    RR20  RR1  RR1  RR1  RR1  RR1  RR1  RR1  RR1  RR1           
VC2 EXT & 
↑RR   
EXT 
(VC2)  RR5  RR10  RR15  RR20                     
Drug Cycle 3 
(14 days)    RR20  RR1  RR1  RR1  RR1  RR1  RR1  RR1  RR1  RR1  RR1  RR1  RR1  RR1  RR1 
DC3 EXT   
EXT 
(DC3)  RR5 
RR1 
(Bloods)                         
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Figure 1. Timeline for acute prazosin administration.
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   Figure 2. Reinforcer seeking.  Mean (± SEM) reinforcer-seeking (bar presses in 20 
   min) on the appetitive testing days for the sucrose-reinforced (white) and ethanol- 
   reinforced (black) groups over one of four doses of prazosin (0, 0.5, 1.0, 1.5 mg/kg) 
   treatments (-30 min). There was a main effect of Treatment [F(3,39)=8.3, p ≤ 0.001] 
   with post hoc analysis showing that all prazosin doses differed from control (*).
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   Figure 3. Reinforcer intake.  Mean (± SEM) total reinforcer intake  (g/kg over 20 min) 
   on consummatory testing days for the sucrose-reinforced (white) and ethanol-reinforced 
   (black) groups over one of four doses of prazosin (0, 0.5, 1.0, 1.5 mg/kg) treatments  
   (-30 min). There was a main effect of Treatment [F(3,36)=7.9, p ≤ 0.001] with post hoc 
   analysis showing that only the high dose of prazosin differed from control (*). 
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   Figure 4. Latency to lever-press.  Mean (± SEM) latency (sec) to first lever-press on 
   appetitive testing days.  Sucrose-reinforced (white) and ethanol-reinforced (black) 
   groups over control and prazosin treatments (-30 min) are shown. RMANOVA 
   indicated an interaction effect such that in the ethanol group only, the high dose of 
   prazosin increased the time to first lever-press [F(3,39)=4.6, p ≤ 0.01].  Because of the 
   high variability of these responses and the absence of a response in some cases 
   (assigned 1200 sec), a Mann-Whitney Rank Sum test at the high dose confirmed these 
   findings (*) (Median values-Appetitive: sucrose 24.4, ethanol 182.6).
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   Figure 5. Latency to lick.  Mean (± SEM) latency (sec) to first lick on consummatory 
   testing days.  Sucrose-reinforced (white) and ethanol-reinforced (black) groups over 
   control and prazosin treatments (-30 min) are shown. RMANOVA indicated an 
   interaction effect such that in the ethanol group only, the high dose of prazosin 
   increased the time to first lick [F(3,39)=4.6, p ≤ 0.01].  Because of the high variability 
   of these responses and the absence of a response in some cases (assigned 1200 sec), a 
   Mann-Whitney Rank Sum test at the high dose confirmed these findings (*) (Median 
   values-Consummatory: sucrose 2.9, ethanol 656.8).
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Figure 6. Timeline for chronic prazosin administration.
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   Figure 7. Chronic ethanol intake.  Top: In the ethanol-reinforced group (n=12), mean 
   (± SEM) ethanol intake (g/kg) over days following either vehicle or prazosin treatment. 
   Bottom: Mean ethanol intake before the start of drug manipulation. 
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   Figure 8. Chronic mean ethanol intake.  Total mean (± SEM) ethanol intake collapsed 
   over all days.
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   Figure 9. Chronic sucrose intake.  In the sucrose-reinforced group (n=11), mean 
   (± SEM) sucrose intake (g/kg) over days following either vehicle or prazosin treatment.
 
 
 
  
 
 
53 
 
 
 
 
 
 
 
 
 
    Figure 10. Chronic mean sucrose intake.  Total mean (± SEM) sucrose intake 
    collapsed over all days. Asterisk indicates a main effect of dose, with all doses of 
    prazosin differing from vehicle.
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   Figure 11. Seeking following prazosin treatment.  Mean (± SEM) lever-press responses 
   during single, non-reinforced sessions in the ethanol and sucrose groups in  
   prazosin-treated rats.  Asterisk indicates a main effect of dose, differing from vehicle.
 
 
 
 
  
55 
 
 
 
 
 
 
 
 
   Figure 12. Latency to lick for ethanol in Experiment 2.  In the ethanol-reinforced group 
   (n=12), mean (± SEM) latency (sec) to first  lick in consummatory sessions.
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Figure 13. Latency to lever-press in Experiment 2.  In ethanol- and sucrose-reinforced 
groups (n=12/n=11, respectively), mean (± SEM) latency (sec) to lever-press on 
appetitive testing days. Asterisk indicates a main effect of dose, with the lowest dose of 
prazosin increasing latency to lever-press in appetitive sessions.
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   Figure 14. Latency to lick for sucrose in Experiment 2.  In the sucrose-reinforced 
   group (n=11), mean (± SEM) latency (sec) to first lick in consummatory sessions. 
 
